Lordkipanidzé Marie, So Derek, Tanguay Jean-François
Faculté de Pharmacie, Université de Montréal, C.P. 6128, Succ. Centre-ville, Montréal, QC, H3C 3J7, Canada.
Research Center, Montreal Heart Institute, 5000 rue Bélanger, Montréal, QC, H1T 1C8, Canada.
Biomark Med. 2016 Aug;10(8):903-18. doi: 10.2217/bmm-2016-0070. Epub 2016 Jul 14.
Despite the overwhelming evidence in support of the efficacy of dual antiplatelet therapy with aspirin and clopidogrel, it is also obvious that not all patients benefit from these drugs to the same extent. This interindividual variability in platelet responses may underlie clinical differences in drug efficacy, with potential for optimization of antiplatelet therapy to prevent ischemic events without excessively increasing bleeding risk. This review presents the current evidence regarding platelet function testing for monitoring of antiplatelet therapy, with emphasis on the prognostic value of platelet function testing to predict ischemic and bleeding events. The potential of platelet function testing to provide personalized antiplatelet therapy is also discussed, with an outlook toward the future of platelet function testing in high-risk individuals.
尽管有大量证据支持阿司匹林和氯吡格雷双联抗血小板治疗的疗效，但显然并非所有患者都能同等程度地从这些药物中获益。血小板反应的个体差异可能是药物疗效临床差异的基础，这为优化抗血小板治疗以预防缺血事件而不过度增加出血风险提供了可能。本综述介绍了目前关于血小板功能检测以监测抗血小板治疗的证据，重点阐述了血小板功能检测对预测缺血和出血事件的预后价值。还讨论了血小板功能检测提供个性化抗血小板治疗的潜力，并展望了高危个体血小板功能检测的未来。
